A Call To Action
To show support for Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device and to help urge the Food and Drug Administration (FDA) to move forward with its Premarket Approval Application (PMAA) you can do any/all of the following:
- E-mail Dr. Margaret Hamburg, commissioner of Food and Drugs, at email@example.com
- E-mail Dr. Jeffery Shuren, director for the Center of Devices and Radiological Health (CDRH), at firstname.lastname@example.org
- Send a letter to the CDRH at: U.S. Food and Drug Administration, 10903 New Hampshire Avenue, W066-5481, Silver Spring, MD 20993. Click here to view a sample of an advocacy support letter for this issue.